Shire to pay $56.5m to settle false claims violations
This article was originally published in Scrip
Executive Summary
Shire has agreed to pay $56.5m to settle civil allegations it violated the False Claims Act (FCA) as a result of its marketing and promotional practices involving its attention deficit/hyperactivity disorder (ADHD) medications Adderall XR (amphetamine/dextroamphetamine mixed salts), Vyvanse (lisdexamfetamine dimesylate) and Daytrana methylphenidate transdermal system) and its ulcerative colitis drugs Lialda (mesalamine) delayed-release tablets and Pentasa (mesalamine).